NEW YORK--(BUSINESS WIRE)--Crossix Solutions, the leader in consumer-centric healthcare analytics, has completed its largest-ever expansion of connected health data—not just in terms of the volume of data, but in its uniqueness as well. This transformative expansion substantially increases the scale of Crossix’s Rx and medical claims data and introduces new types of data, including hospital, clinical/real-world data (RWD), and lab results.
By harnessing the power of Crossix’s technology and unlocking the value of connecting a wider breadth of health and non-health data, pharmaceutical brands, media agencies, and other companies across the healthcare landscape can now gain deeper audience and campaign insights, while driving improved patient outcomes and business results. With this expanded, connected data set now comprised of more than 250 million U.S. consumers, Crossix’s enhanced audience reach, measurement and optimization solutions offer an unrivaled ability to better understand patient behaviors and campaign performance across the following:
- An expanded set of specialty drugs, including Biologics
- Oncology treatments
- Rare diseases & low-incidence conditions
- Medical devices
- Hospital in-patient and out-patient dynamics
- Lab data (orders & results) combined with clinical data
- Insurer-sourced claims to ensure perfect coverage at the patient level
The expansion also encourages the healthcare industry to reimagine the definition of success at different stages of the patient continuum by introducing an array of new and actionable metrics, beyond the traditional focus on prescription fills and new patient starts.
Multiple use cases, across various condition categories, are enabled with these exciting data connections. For example, a diabetes brand can now achieve a more comprehensive view across the entire patient journey by monitoring pre-risk data—such as BMI, lab data, and food purchases—to diagnosis, treatment, doctor visitation, test results, and complications, among many others, all while maintaining HIPAA compliance.
“The ability to connect all of these different data types represents a truly first-of-its-kind opportunity for the healthcare industry,” explained Asaf Evenhaim, CEO and co-founder of Crossix. “It provides our clients with a much deeper understanding of health and non-health behaviors, which is imperative for improving patient outcomes and business results.”
What our industry colleagues are saying:
“In the past few years, our clients have made significant progress in better understanding the various milestones and nuances along the patient journey,” said David Windhausen, executive vice president at Intouch Solutions. “Advances in data and technology have been key to this progress, but questions still remain. Many of these questions can now be answered through this expanded, more comprehensive data set that enables a much more granular and holistic view into ever-changing patient dynamics.”
“The value of deeper clinical data, combined with predictive analytics, can deliver greater insights for life sciences companies to create more valuable customer interactions,” said Ed Manko, director of Veeva OpenData strategy at Veeva Systems. “As a member of the Veeva OpenData Partner Program, Crossix and Veeva are working together to provide comprehensive and accurate data across the industry.”
“While claims data is certainly useful, there are also limitations when it comes to the granularity of insights you can glean from it,” said Dori Cappola, SVP media at Klick Health. “By connecting a greater variety of clinical, lab results, and biologics data, we can track even more key patient milestones across the patient journey, like diagnoses, initial treatment, and adherence for instance, with greater precision and specificity.”
“Data has the power to drive business results, but most importantly, it can enhance people’s lives,” said Rick Erwin, president, Audience Solutions at Acxiom. “Connecting this greater breadth and depth of health data to our consumer data is a game-changer for the industry’s ability to improve patients’ health and well-being.”
“Being able to incorporate clinical data such as patient charts and doctor’s notes, along with Rx and other data points, is a game-changer,” said Courtney Johnson, VP of client strategy at Good Apple. “Having this broader data to work with can only enhance the relevance and timeliness of how we target and communicate with health consumers.”
To learn more about Crossix, visit www.crossix.com.
About Crossix Solutions
Crossix partners with leading healthcare and media companies to plan, measure and optimize their marketing and communication initiatives. With deep consumer and healthcare professional expertise, Crossix delivers hard-to-come-by audience and campaign insights to inform strategic business decisions and drive improved patient outcomes. Data-driven and data-proven, the patented Crossix methodology and differentiated technology enable critical connections across its proprietary data network of Rx, OTC, medical, clinical, media and consumer data to ensure more actionable cross-channel measurement with best-in-class privacy safeguards far exceeding HIPAA requirements. The unique Crossix technology aggregates insights from across the data network to pinpoint marketing initiatives that activate the right audiences and generate incremental impact. Founded in 2004, Crossix is headquartered in New York City.